European urology

(ISSN: 0302-2838, 1873-7560)

Table of Contents

From European urology

2018 -

  • External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. 
  • Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. 
  • Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. 
  • Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. 
  • Radiofrequency-induced Thermochemotherapy for Recurrent Non-muscle-invasive Bladder Cancer: A New Treatment for an Unmet Need? 
  • Identification of Potential Novel Candidates for Understanding Racial Differences in Prostate Cancer. 
  • Devil in the Detail: Intratumour Heterogeneity and Personalised Medicine for Bladder Cancer. 
  • Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. 
  • Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. 
  • BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). 
  • Towards Next-generation Urine-based Prostate Cancer Risk Stratification. 
  • Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up. 
  • The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. 
  • Lessons Learned from the Global Epidemiology of Kidney Cancer: A Refresher in Epidemiology 101. 
  • Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. 
  • Bladder Tumors with Mixed Histology: What Is the Basis for the Heterogeneity? 
  • Harnessing New Media Tools in Patient Information. 
  • Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52. 
  • Re: Dipen J. Parekh, Isidinha M. Reis, Erik P. Castle, et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial. Lancet 2018;391:2525-36: Blood Loss in Robot-assisted Radical Cystectomy: An Important Patient Benefit. 
  • Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. 
  • Personalized Prostate Cancer Screening Based on a Single Midlife Prostate-specific Antigen Measurement. 
  • Is Androgen Deprivation Therapy "Another Deficient Therapy" for Gleason Score 9-10 Prostate Cancer? 
  • Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants. 
  • Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. 
  • Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 74, 2018, 294-306. 
  • "Ride the Green Light": Indocyanine Green-marked Off-clamp Robotic Partial Nephrectomy for Totally Endophytic Renal Masses. 
  • Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma. 
  • Re: Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack. Approved Checkpoint Inhibitors in Bladder Cancer: Which Drug Should Be Used When? Ther Adv Med Oncol 2018;10:1758835918788310: Knowing PD-L1 Status is Not Enough: Applying a Molecular Subtype Approach to Bladder Cancer is Also Needed. 
  • Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging? 
  • The Combination of Enzalutamide and Opioids: A Painful Pitfall? 
  • Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men. 
  • An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis. 
  • Epidemiology of Renal Cell Carcinoma. 
  • The Learning Curve for Robot-assisted Partial Nephrectomy: Impact of Surgical Experience on Perioperative Outcomes. 
  • Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. 
  • Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study. 
  • Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. 
  • Do We Truly Care About the Functional Outcomes for Renal Cancer Patients? Multidisciplinarity Is Still Far Away. 
  • Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52. 
  • Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91. 
  • A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. 
  • Molecular Subtypes of Bladder Cancer: Academic Exercise or Clinical Relevance? 
  • Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade. 
  • Clinical Efficacy of Injection and Mechanical Therapy for Peyronie's Disease: A Systematic Review of the Literature. 
  • "Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. 
  • Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y.C. Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium. 
  • A Nomogram to Predict Significant Estimated Glomerular Filtration Rate Reduction After Robotic Partial Nephrectomy. 
  • Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91. 
  • Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. 
  • A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. 
  • Reply to Runqiang Yuan's Letter to the Editor re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol 2018;73:706-12. 
  • Low Testosterone and Prostate Cancer: Is the Protection Real? 
  • Re: Riccardo Bertolo, Riccardo Autorino, Giuseppe Simone, et al. Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.05.004. 
  • Reply to Zhenjie Wu and Linhui Wang's Letter to the Editor re: Riccardo Bertolo, Riccardo Autorino, Giuseppe Simone, et al. Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.05.004. 
  • Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity. 
  • Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. 
  • Statin Therapy to Improve Prostate Cancer Outcomes: Who, When, and for How Long? 
  • New Insights into Ejaculatory Frequency and Prostate Cancer Risk: Association, Causation, or What Do We Have to Lose? 
  • Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. 
  • Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer. 
  • An Insight into the "Dark Matter" of Kidney Cancer. 
  • Re: Enzalutamide in Men with Nonmetastatic, Castration-resistant Prostate Cancer. 
  • Intralesional and Mechanical Therapies for Peyronie's Disease: A Road Anything but Straight. 
  • Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. 
  • Treatment of Bladder Pain Syndrome: One Size May Not Fit All. 
  • Re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol 2018;73:706-12. 
  • Current Insights in the Management of High-risk Prostate Cancer: Still More Questions than Answers. 
  • T1 High-grade Bladder Cancer: The Search for the Optimal Management Continues. 
  • Metastasis-free Survival-Progress or Lowering the Bar on Nonmetastatic Prostate Cancer? 
  • Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma. 
  • Re: Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial. 
  • Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial. 
  • Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. 
  • Detrusor Underactivity and the Underactive Bladder: A Systematic Review of Preclinical and Clinical Studies. 
  • Re: Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial. 
  • Robot-assisted AMS-800 Artificial Urinary Sphincter Bladder Neck Implantation in Female Patients with Stress Urinary Incontinence. 
  • Managing Nonmetastatic Castration-resistant Prostate Cancer. 
  • Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma. 
  • Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship Between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. 
  • Re: Isabel Rauscher, Charlotte Düwel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol 2018;73:656-61: Clinical Significance of Prostate-specific Membrane Antigen Immunohistochemistry and Role of the Uropathologists. 
  • Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2? 
  • Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. 
  • Re: Comparison of Prostatic Artery Embolization (PAE) Versus Transurethral Resection of the Prostate (TURP) for Benign Prostatic Hyperplasia: Randomised, Open Label, Non-inferiority Trial. 
  • Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies. 
  • Robot-assisted Partial Adrenalectomy for the Treatment of Conn's Syndrome: Surgical Technique, and Perioperative and Functional Outcomes. 
  • The Promise and Perils of Sequencing Individual Prostate Cancer Nuclei. 
  • A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome. 
  • Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. 
  • Adjuvant Therapy for Resected Renal Cell Carcinoma-Still Searching. 
  • Re: Safety of Vaginal Mesh Surgery Versus Laparoscopic Mesh Sacropexy for Cystocele Repair: Results of the Prosthetic Pelvic Floor Repair Randomized Controlled Trial. 
  • How Are Gleason Scores Categorized in the Current Literature: An Analysis and Comparison of Articles Published in 2016-2017. 
  • Re: Molecular Subtypes of Clear-cell Renal Cell Carcinoma Are Prognostic for Outcome After Complete Metastasectomy. 
  • Reply to Vincenzo Di Nunno, Matteo Santoni, Alessia Cimadamore, Nicola Battelli, and Francesco Massari's Letter to the Editor re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, et al. Updates in the Eight Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560-9. 
  • Retrograde Release of the Neurovascular Bundle with Preservation of Dorsal Venous Complex During Robot-assisted Radical Prostatectomy: Optimizing Functional Outcomes. 
  • Re: Detrusor Acontractility After Acute Spinal Cord Injury-Myth or Reality? 
  • Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. 
  • Re: Differences in Survival Associated with Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. 
  • Analysis of the Enteric Microbiome: First Tentative Steps Towards a Comprehensive Work-up of Prostate Cancer? 
  • Re: The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative outcomes after Robot-assisted Radical Prostatectomy. 
  • Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. 
  • Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy. 
  • Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. 
  • Re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium. 
  • Tradeoffs in Refining the Diagnosis of Prostate Cancer. 
  • Finding a Needle in the Haystack: The Search for Germline Variants Associated with Prostate Cancer Clinical Outcomes. 
  • Reply to John T. Leppert and James D. Brooks' Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.01.043. 
  • Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.04.029. 
  • Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer. 
  • Corrigendum re: "A Larger Prospective Study is Needed when Judging Robotic Radical Nephrectomy" [Eur Urol 2018;74:123-9]. 
  • Simultaneous Bilateral Endoscopic Surgery (SBES) for Patients with Bilateral Upper Tract Urolithiasis: Technique and Outcomes. 
  • Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. 
  • Re: Exercise and Cancer Treatment: Balancing Patient Needs. Lancet Oncol 2018;19:715: Cancer Prevention and Treatment: More than Exercising. 
  • Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. 
  • Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. 
  • Therapeutic Discovery for Castration Resistant Prostate Cancer: Patient-derived Xenograft Modelling Brings New Options to the Table. 
  • Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.01.043. 
  • Re: Giorgio Gandaglia, Carlo Andrea Bravi, Paolo Dell'Oglio, et al. The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.025. 
  • Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560-9: Tumour, Node, and Metastasis Staging System for Urological Malignancies: Are We Ready for the Next Step? 
  • Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer. 
  • Reply to Riccardo Bertolo's Letter to the Editor re: Giorgio Gandaglia, Carlo Andrea Bravi, Paolo Dell'Oglio, et al. The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. Eur Urol 2018;74:4-7. 
  • Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. 
  • Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. 
  • Retrosigmoid Versus Traditional Ileal Conduit for Urinary Diversion After Radical Cystectomy. 
  • Corrigendum re: "The Impact of Prostate Size, Median Lobe, and Prior Benign Prostatic Hyperplasia Intervention on Robot-Assisted Laparoscopic Prostatectomy: Technique and Outcomes" [Eur Urol 2011;59:595-603]. 
  • Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing. 
  • Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures. 
  • Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. 
  • Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. 
  • Differential Gene Expression in Prostate Tissue According to Ejaculation Frequency. 
  • Focal Therapy for Prostate Cancer: A More Vehement View of the Approach Could Translate into Real Benefits for Our Patients. 
  • Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. 
  • 99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. 
  • Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain: A Systematic Review of the Literature. 
  • Hyperaccuracy Three-dimensional Reconstruction Is Able to Maximize the Efficacy of Selective Clamping During Robot-assisted Partial Nephrectomy for Complex Renal Masses. 
 
 

Journal Information